Last updated on October 2018

A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma


Brief description of study

Mepolizumab, a humanized monoclonal antibody, has been developed as an add-on treatment for subjects with severe asthma with eosinophilic inflammation. Current asthma treatment guidelines offer minimal options for the severe asthmatic subjects on intensive therapy with frequent exacerbations. There is a significant unmet medical need to provide better treatment options for this segment of the asthma population. Thus, this study is designed to evaluate the efficacy and safety of mepolizumab in Chinese severe asthmatic subjects with eosinophilic inflammation. A total number of 300 subjects will be randomized in 1:1 ratio to receive either mepolizumab or placebo along with existing standard of care therapy. The maximum study duration will be 56 weeks.

Clinical Study Identifier: NCT03562195

Contact Investigators or Research Sites near you

Start Over

US GSK Clinical Trials Call ...

GSK Investigational Site
Guangzhou, China
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Wenzhou, China
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Shanghai, China
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Changchun, China
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Urumqi, China
  Connect »